Publications by authors named "Thomas Musliner"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

20,028

Total Likes

428

Extended Reach

524,080

Social Features

89
P
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT.
Robert P Giugliano, Baris Gencer, Stephen D Wiviott, Jeong-Gun Park, Charles S Fuchs, Thomas A Musliner

JACC CardioOncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin.
Michael G Nanna, Ann Marie Navar, Robert P Giugliano, Jennifer A White, Yuliya Lokhnygina, Thomas A Musliner

J Am Coll Cardiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Peter P Toth, Alberico L Catapano, Michel Farnier, Joanne Foody, Joanne E Tomassini, Thomas A Musliner

Am J Cardiol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
Michael A Blazing, Robert P Giugliano, James A de Lemos, Christopher P Cannon, Andrew Tonkin, Thomas A Musliner

Am Heart J· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia.
D Meeike Kusters, Maria Caceres, Mauricio Coll, Cynthia Cuffie, Claude Gagné, Thomas A Musliner

J Pediatr· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Michael A Blazing, Robert P Giugliano, Christopher P Cannon, Thomas A Musliner, Andrew M Tershakovec

Am Heart J· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Helmut Steinberg, Matt S Anderson, Thomas Musliner, Mary E Hanson, Samuel S Engel

Vasc Health Risk Manag· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.
Michael H Davidson, Jason Voogt, Jayraz Luchoomun, Julie Decaris, Salena Killion, Thomas Musliner

Atherosclerosis· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal sterol transporters and cholesterol absorption inhibition.
Harry R Davis, Andrew M Tershakovec, Joanne E Tomassini, Thomas Musliner

Curr Opin Lipidol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
Robert M Califf, Yuliya Lokhnygina, Christopher P Cannon, Michael E Stepanavage, Carolyn H McCabe, Thomas A Musliner

Am Heart J· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.
Susan G Lakoski, Fang Xu, Gloria L Vega, Scott M Grundy, Manisha Chandalia, Thomas A Musliner

J Clin Endocrinol Metab· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men.
Thomas Sudhop, Michael Reber, Diane Tribble, Aditi Sapre, William Taggart, Thomas Musliner

J Lipid Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Christopher P Cannon, Robert P Giugliano, Michael A Blazing, Robert A Harrington, John L Peterson, Thomas A Musliner

Am Heart J· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Diane L Tribble, Michel Farnier, Geraldine Macdonell, Inna Perevozskaya, Michael J Davies, Thomas A Musliner

Metabolism· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
Gerd Assmann, Frank Kannenberg, Dena R Ramey, Thomas A Musliner, Stephen W Gutkin

Curr Med Res Opin· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Leiv Ose, Robert Reyes, Amy O Johnson-Levonas, Aditi Sapre, Diane L Tribble, Thomas Musliner

Clin Ther· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Striated muscle safety of ezetimibe/simvastatin (Vytorin).
Michael H Davidson, Darbie Maccubbin, Michael Stepanavage, John Strony, Thomas Musliner

Am J Cardiol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In response to 'ezetimibe-induced hyperlipidaemia' case report.
Harold Bays, Thomas Musliner

Int J Clin Pract· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998.
Terje R Pedersen, Anders G Olsson, Ole Faergeman, John Kjekshus, Hans Wedel, Thomas A Musliner

Atheroscler Suppl· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
Claude Gagné, Harold E Bays, Stuart R Weiss, Pedro Mata, Katherine Quinto, Thomas A Musliner

Am J Cardiol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Frank Lanza, Bruce Sahba, Howard Schwartz, Steven Winograd, James Torosis, Thomas Musliner

Am J Gastroenterol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis